Abstract:
We have examined the primary immune response, the numbers of the total T (T-11+) cells, T-helper (T4+) cells, T-suppressor (T8+) cells, NK cells (Leu7+) and the level of serum IgG in 83 healthy male heterosexuals and compared the data to those obtained from 12 clinically diagnosed AIDS patients and 92 asymptomatic male homosexuals. The absolute number of total T (T11) and T helper (T4) cell populations were significantly reduced among most of the asymptomatic homosexual males and even more decreased in the AIDS patients. In contrast, the absolute numbers of T suppressor cells (T8) remained virtually unaltered in the 3 study populations. The absolute numbers of circulating killer cells were similar in the controls and the homosexual subjects but significantly reduced in the AIDS patients. Furthermore, all 12 AIDS patients exhibited a significantly depressed NK cell activity which in most cases correlated with the reduced absolute number of NK (Leu7+) cells as well as T helper cells (T4) and T4/T8 ratios. The NK-cell activity in clinically diagnosed AIDS patients could not be normalized by addition of alpha IFN or IL2. Three distinctive subgroups with normal (N-NK), significantly heightened (H-NK) and markedly lowered (L-NK) NK activity could be readily identified among the apparently well homosexual male population. The subgroups responded to alpha IFN and IL2 in an apparently independent fashion. The N-NK and L-NK groups displayed a marginal to no response to in vitro treatment with alpha IFN and IL2. However, the NK cell activity in the H-NK group was moderately to strongly inhibited by inclusion of the 2 immunomodifiers.(ABSTRACT TRUNCATED AT 250 WORDS)
Keywords: Acquired Immunodeficiency Syndrome/BLOOD/*IMMUNOLOGY Adult Aged Comparative Study Homosexuality Human In Vitro Interferon Type I/*PHARMACOLOGY Interleukin-2/*IMMUNOLOGY Killer Cells, Natural/*IMMUNOLOGY Leukocyte Count Male Middle Age Support, Non-U.S. Gov't T-Lymphocytes, Helper-Inducer/IMMUNOLOGY T-Lymphocytes, Suppressor-Effector/IMMUNOLOGY JOURNAL ARTICLE
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
